The Number Your Kidneys Write All Day: Cystatin C and the Quiet Upgrade to the Kidney Test

The blood comes out of the arm in the ordinary way — one tube — and goes into the centrifuge, and what the lab will measure is a small protein almost nobody has heard of. Cystatin C. Every nucleated cell in the body makes it, at a nearly constant rate, all day, every day. It drifts in the plasma until it reaches the kidney, where the glomeruli filter it freely out of the blood — and then the tubules reabsorb it and break it down, so almost none escapes into urine. What remains circulating is a running balance: production, constant, against filtration, variable. The concentration is a number the kidneys are writing, continuously, about themselves.

For decades, the same question was answered with creatinine, a byproduct of muscle — which meant the answer shifted with muscle mass, diet, age, and sex. Cystatin C is largely independent of all of that. The two numbers, set side by side in the same patient, do not always agree; and when they disagree, the disagreement is usually meaningful — a quiet argument between two estimates that one of them is losing.

That is the question here: whether cystatin C-based estimated GFR measures kidney function better and predicts hard outcomes more strongly. The defensible answer: yes on both counts, across very large data — with honest caveats about where it fails and what else moves it.

The reclassification evidence

In a consortium meta-analysis of roughly 90,750 people, reported in Nature Medicine, filtration estimated by cystatin C markedly improved risk reclassification for death, cardiovascular disease, and end-stage kidney disease. In general-population cohorts, it flags more chronic kidney disease than creatinine alone: 13.7% versus 9.7% below an eGFR of 60. A 2013 New England Journal of Medicine analysis set cystatin C against creatinine for determining risk based on kidney function and found the combination of the two markers strongest. It independently predicts mortality in the general population and in heart failure — including, in a 2024 study, long-term, all-cause, and cardiovascular mortality in US adults with metabolic syndrome — with particular value in older adults and people with atypical muscle mass — exactly the patients creatinine reads least faithfully.

The guideline has already moved

The 2021 race-free CKD-EPI equations, published in the New England Journal of Medicine, combine creatinine and cystatin C. The KDIGO 2024 guideline recommends estimating GFR from both markers together when cystatin C is available. The confirmatory role is no longer exotic; it is the written standard of care, cementing cystatin C as the reference second measure of kidney function worldwide.

The complications, kept in view

The evidence is not uniform. In a sub-Saharan African validation, cystatin C did not outperform creatinine — a reminder that equations travel imperfectly across populations. The protein's level is itself shifted by thyroid dysfunction, corticosteroids, obesity, smoking, and inflammation — nearly constant production is a good approximation, not a law of nature. And the test costs more than creatinine, which is why it remains a confirmatory tool rather than a universal one — the second opinion in kidney medicine, not the first.

Practical meaning

For a reader with a borderline creatinine-based eGFR, a cystatin C confirmatory test is exactly what current guidelines contemplate — a question for their clinician, not a self-diagnosis, and not a number to chase with supplements. This evidence describes the biomarker and the eGFR equations themselves, not this specific commercial test product.

The tube sits in the centrifuge, spinning down toward one small protein. All day, the kidneys have been writing the number. The quiet change, decades in the making, is that medicine has finally learned to read it properly. Educational, not medical advice.